Dupont Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Dupont Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-19,508	Closed	-$350K	–	1060
2017 Q4	$350K	Sell	19,508 -34,343	-64%	-$423K	0.01%	732
2017 Q3	$635K	Buy	+53,851	New	+$604K	0.01%	623
2017 Q2	–	Sell	-66,853	Closed	-$735K	–	1033
2017 Q1	$735K	Sell	66,853 -19,175	-22%	-$223K	0.02%	597
2016 Q4	$1.17M	Sell	86,028 -28,676	-25%	-$400K	0.03%	452
2016 Q3	$1.41M	Sell	114,704 -16,054	-12%	-$189K	0.03%	377
2016 Q2	$1.43M	Buy	130,758 +39,705	+44%	+$444K	0.03%	367
2016 Q1	$995K	Buy	91,053 +47,511	+109%	+$600K	0.02%	452
2015 Q4	$753K	Hold	43,542	–	–	0.02%	522
2015 Q3	$865K	Hold	43,542	–	–	0.02%	469
2015 Q2	$715K	Buy	+43,542	New	+$755K	0.02%	480

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Dupont Capital Management's SCMP Position: Q1 2018 in Review

Dupont Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 19,508 shares — an estimated $350K sold.

Dupont Capital Management first reported a position in SCMP in Q2 2015 and held it in 10 quarters. The position peaked at $1.43M in Q2 2016. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Dupont Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Dupont Capital Management sold 19,508 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $350K.
Dupont Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Dupont Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.43M in Q2 2016.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Dupont Capital Management's 13F filing for Q1 2018, filed 2 May 2018.